Defence against antimicrobial peptides:Different strategies in Firmicutes by Revilla-Guarinos, Ainhoa et al.
        
Citation for published version:
Revilla-Guarinos, A, Gebhard, S, Mascher, T & Zúñiga, M 2014, 'Defence against antimicrobial peptides:









This is the peer reviewed version of the following article: Revilla-Guarinos, A, Gebhard, S, Mascher, T & Zúñiga,
M 2014, 'Defence against antimicrobial peptides: Different strategies in Firmicutes' Environmental Microbiology,
vol 16, no. 5, pp. 1225-1237., which has been published in final form at http://dx.doi.org/10.1111/1462-




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. May. 2019
1	  
	  
TITLE	  Defence	  against	  antimicrobial	  peptides:	  different	  strategies	  in	  Firmicutes	  1	  
	  2	  
AUTHORS	  Ainhoa	  Revilla-­‐Guarinos	  1,	  Susanne	  Gebhard	  2,	  Thorsten	  Mascher	  2,	  Manuel	  3	  
Zúñiga1	  *	  4	  
	  5	  
1	  Departamento	  de	  Biotecnología,	  Instituto	  de	  Agroquímica	  y	  Tecnología	  de	  Alimentos	  6	  
(IATA),	  Consejo	  Superior	  de	  Investigaciones	  Científicas	  (CSIC),	  Avda.	  Agustín	  Escardino	  7	  
7,	  46980	  Paterna,	  Valencia,	  Spain	  8	  
2	   Ludwig-­‐Maximilians-­‐Universität	   München,	   Department	   Biologie	   I,	   Mikrobiologie,	  9	  
Großhaderner	  Str.	  2-­‐4,	  D-­‐82152,	  Planegg-­‐Martinsried,	  Germany	  10	  
	  11	  
*	  Corresponding	  author;	  Tel	  +34	  963900022;	  Fax	  +34	  963636301	  12	  
E-­‐mail:	  btcman@iata.csic.es	  13	  
	  14	  
RUNNING	  TITLE	  Antimicrobial	  peptide	  resistance	  in	  Firmicutes	  15	  




The	  Firmicutes	  constitute	  a	  phylum	  of	  bacteria	  that	  can	  be	  found	  in	  a	  wide	  variety	  of	  habitats,	  18	  
from	   soil	   to	   the	   gastrointestinal	   tract	   of	   animals,	   where	   they	   have	   to	   thrive	   in	   complex	  19	  
communities.	   Competition	   in	   these	   communities	   usually	   involves	   the	   production	   of	  20	  
compounds	   such	   as	   antimicrobial	   peptides	   to	   eliminate	   competitor	   organisms.	   Animals	   and	  21	  
plants	   also	   produce	   antimicrobial	   peptides	   to	   control	   their	   associated	   microbiota.	   In	   turn,	  22	  
defence	   mechanisms	   have	   evolved	   to	   prevent	   the	   action	   of	   these	   compounds.	   The	   close	  23	  
association	  of	  some	  Firmicutes	  with	  humans	  as	  prominent	  pathogens	  or	  commensal	  organisms	  24	  
has	   driven	   a	   considerable	   research	   effort	   on	   defence	   mechanisms	   used	   by	   these	   bacteria	  25	  
against	   antimicrobial	   compounds.	   This	   review	   focuses	   on	   the	  most	   recent	   advances	   on	   two	  26	  
well	  characterized	  defence	  mechanisms	  against	  antimicrobial	  peptides:	  the	  modification	  of	  the	  27	  
cell	  wall	  by	  D-­‐alanylation	  and	  the	  role	  of	  peptide	  antibiotic-­‐specific	  ABC	  transporters.	  28	  
	  29	  
Introduction	  30	  
Antimicrobial	  peptides	  (AMPs)	  are	  a	  diverse	  group	  of	  compounds	  produced	  by	  bacteria	  as	  well	  31	  
as	  higher	  organisms,	   including	  animals	  and	  humans.	  Among	  the	  most	  prominent	  examples	  of	  32	  
bacterial	  AMPs	  are	  the	  heavily	  modified	   lantibiotics,	  a	  class	  of	  bacteriocins	   that	  were	  named	  33	  
after	   their	   characteristic	   lanthionine	   or	   methyllanthionine	   residues.	   Their	   structure	   can	   be	  34	  
either	   elongated,	   for	   example	   in	   nisin	   (Fig.	   1A)	   or	   subtilin,	   or	   globular,	   as	   is	   the	   case	   for	  35	  
mersacidin	  or	  actagardine	   (Bierbaum	  and	  Sahl,	  2009).	  Non-­‐lantibiotic	  bacteriocins	  are	  similar	  36	  
in	  size	  to	  lantibiotics	  (<10	  kDa),	  but	  are	  not	  as	  extensively	  modified	  (Cotter	  et	  al.,	  2005).	  Both	  37	  
classes	   of	   bacteriocins	   are	   ribosomally	   synthesized	   and	   mainly	   produced	   by	   Firmicutes	  38	  
bacteria.	  Gram-­‐negative	  bacteria	  also	  produce	  AMPs,	  usually	   referred	   to	  as	  microcins.	  These	  39	  
are	  ribosomally	  synthesized,	  essentially	  hydrophobic	  peptides	  that	  in	  some	  cases	  are	  subjected	  40	  
to	  post-­‐translational	  modifications	   (Rebuffat,	   2012).	   In	   addition,	  many	  bacteria	   also	  produce	  41	  
non-­‐ribosomally	  synthesized	  peptides	  such	  as	  the	  small	  circular	  metallo-­‐peptide	  bacitracin	  (Fig.	  42	  
3	  
	  
1A)	   (Johnson	   et	   al.,	   1945;	   Economou	   et	   al.,	   2013),	   or	   lipodepsipeptides	   such	   as	   ramoplanin	  43	  
(Fig.	   1A)	   or	   enduracidin	   (Fang	   et	   al.,	   2006).	   AMPs	   also	   comprise	   a	   component	   of	   the	   innate	  44	  
immune	   system	   of	   higher	   organisms	   such	   as	   protegrins	   (Fig.	   1A).	   Another	   example	   of	  45	  
mammalian	  AMPs	  are	  the	  defensins,	  which	  are	  produced	  for	  example	  in	  epithelial	  and	  immune	  46	  
cells	   of	   humans.	   They	   are	   about	   30-­‐40	   amino	   acids	   long	   cysteine-­‐rich	   peptides	   and	   adopt	   a	  47	  
conformation	  stabilized	  by	  disulfide	  bridges	  (Yount	  and	  Yeaman,	  2013).	  With	  the	  exception	  of	  48	  
microcins,	   the	   examples	   mentioned	   above	   share	   a	   predominant	   positive	   charge	   and	   are	  49	  
therefore	   also	   referred	   to	   as	   cationic	   AMPs	   (CAMPs).	   Many	  more	   examples	   exist	   and	   have	  50	  
been	  extensively	  reviewed	  elsewhere	  (see	  for	  example	  (Breukink	  and	  de	  Kruijff,	  2006;	  Nguyen	  51	  
et	  al.,	  2011;	  Yount	  and	  Yeaman,	  2013).	  52	  
AMPs	   inhibit	  bacterial	   growth,	  either	   to	  provide	  a	   competitive	  advantage	   to	   the	  producer	   in	  53	  
mixed	   bacterial	   populations	   or	   as	   a	   host	   defence	   mechanism	   against	   pathogens	   of	   higher	  54	  
organisms.	   To	   combat	   this,	   the	   targeted	   bacteria	   have	   to	   be	   able	   to	   detect	   and	   respond	   to	  55	  
AMPs	   in	   their	   environment.	   The	   sensitivity	   and	   efficiency	   of	   these	   processes	   are	   important	  56	  
factors	  for	  the	  survival	  of	  bacteria	  in	  competitive	  habitats	  such	  as	  the	  soil	  or	  the	  intestinal	  tract	  57	  
of	  mammals.	  58	  
The	  primary	  mode-­‐of-­‐action	  of	  the	  AMPs	  addressed	  in	  this	  review	  is	  the	  inhibition	  of	  cell	  wall	  59	  
synthesis	   (Fig.	   1B),	   although	   additional	   activities	   have	   been	   described	   for	   some	   compounds,	  60	  
e.g.	  pore-­‐formation	  by	  nisin-­‐type	  lantibiotics	  (Schneider	  and	  Sahl,	  2010;	  Scherer	  et	  al.,	  2013)	  or	  61	  
disturbance	   of	   membrane	   function	   by	   bacitracin	   (Ming	   and	   Epperson,	   2002;	   Schneider	   and	  62	  
Sahl,	  2010;	  Economou	  et	  al.,	  2013).	  Details	  of	  the	  synthesis	  of	  the	  peptidoglycan	  polymer	  that	  63	  
constitutes	   the	   bacterial	   cell	   wall	   have	   been	   reviewed	   elsewhere	   (van	   Heijenoort,	   2007;	  64	  
Bouhss	   et	   al.,	   2008).	   In	   brief,	   the	   biosynthetic	   cycle	   is	   initiated	   on	   the	   cytoplasmic	   side	   by	  65	  
assembly	   of	   precursor	   molecules	   and	   their	   attachment	   to	   the	   lipid	   carrier	   undecaprenyl-­‐66	  
phosphate	   (UP;	   Fig.	   1B).	   The	   resulting	   complex	   of	   N-­‐acetylglucosamine-­‐N-­‐acetylmuramyl-­‐67	  
pentapeptide,	  covalently	  coupled	  to	  the	  lipid	  carrier	  via	  a	  pyrophosphate	  linker	  is	  referred	  to	  68	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as	   lipid	   II	   (Fig.	   1B)	   (van	   Heijenoort,	   2007).	   After	   flipping	   of	   lipid	   II	   to	   the	   outer	   face	   of	   the	  69	  
cytoplasmic	   membrane	   (Mohammadi	   et	   al.,	   2011),	   the	   peptidoglycan	   subunits	   are	  70	  
incorporated	  into	  the	  growing	  cell	  wall.	  This	  step	  is	  the	  target	  for	  many	  CAMPs	  (Fig.	  1B),	  e.g.	  71	  
the	   lantibiotics,	  which	  bind	   to	   the	  pyrophosphate	  moiety	  of	   lipid	   II	   on	   the	  outer	   face	  of	   the	  72	  
membrane	  (Bonev	  et	  al.,	  2004;	  Hsu	  et	  al.,	  2004).	  	  73	  
After	  removal	  of	  the	  peptidoglycan	  precursors,	  the	  lipid	  carrier	  remains	  in	  the	  pyrophosphate	  74	  
form	  (UPP),	  which	  is	  dephosphorylated	  by	  UPP-­‐phosphatases	  (Bouhss	  et	  al.,	  2008)	  and	  flipped	  75	  
back	   to	   the	   cytoplasmic	   face	   of	   the	  membrane	   (Fig.	   1B).	   This	   recycling	   step	   is	   inhibited	   by	  76	  
bacitracin,	   which	   tightly	   binds	   to	   the	   pyrophosphate	   group	   and	   thus	   prevents	   the	  77	  
dephosphorylation	   reaction	   (Fig.	   1B)	   (Siewert	   and	   Strominger,	   1967;	   Storm	   and	   Strominger,	  78	  
1973;	   Schneider	   and	   Sahl,	   2010;	   Economou	   et	   al.,	   2013).	   CAMPs	   therefore	   appear	   to	   act	   as	  79	  
competitive	   inhibitors	   of	   cell	  wall	   synthetic	   enzymes,	  which	   is	   in	   contrast	   to	   the	   irreversible	  80	  
inactivation	   of	   penicillin	   binding	   proteins	   by	   the	   paradigmatic	   cell	   wall-­‐active	   β-­‐lactam	  81	  
antibiotics	   (Fisher	   et	   al.,	   2005)	   and	   is	   an	   important	   factor	   to	   consider	  when	   studying	   CAMP	  82	  
resistance.	  83	  
To	  counteract	  CAMP	  action,	  bacteria	  have	  developed	  a	  broad	  range	  of	  resistance	  mechanisms,	  84	  
which	   include	   drug-­‐specific	   responses	   such	   as	   proteolytic	   degradation	   (Sun	   et	   al.,	   2009)	   or	  85	  
increased	  production	  of	  the	  inhibited	  enzyme	  (Cao	  and	  Helmann,	  2002),	  as	  well	  as	  less	  specific	  86	  
strategies	   such	  as	  biofilm	   formation	   (Otto,	  2006).	  This	   review	  will	   concentrate	  on	   two	  major	  87	  
and	  widely	  distributed	   resistance	  mechanisms	  employed	  by	   Firmicutes	   to	   counteract	  CAMPs	  88	  
that	  have	  recently	  gained	  a	  significant	  amount	  of	  attention:	  changes	  in	  cell	  surface	  charge	  and	  89	  
AMP	  detoxification	  by	  transporters.	  90	  
One	  way	   of	   relieving	   inhibition	   by	   CAMPs	   competing	   for	   substrate	   binding	   is	   to	   reduce	   the	  91	  
access	   of	   the	   peptides	   to	   the	   surface	   of	   the	   cytoplasmic	  membrane,	   i.e.	   the	   location	   of	   its	  92	  
target	  molecules.	   The	   best	   understood	  mechanisms	   to	   achieve	   this	   are	   the	   D-­‐alanylation	   of	  93	  
teichoic	  acids,	   catalyzed	  by	   the	  DltABCD	  system	   (Perego	  et	  al.,	   1995;	  Neuhaus	  and	  Baddiley,	  94	  
5	  
	  
2003;	   McBride	   and	   Sonenshein,	   2011;	   Reichmann	   et	   al.,	   2013),	   and	   the	   lysinylation	   of	  95	  
membrane	  phospholipids	  by	  MprF	  (Peschel	  et	  al.,	  2001;	  Oku	  et	  al.,	  2004;	  Andrä	  et	  al.,	  2011).	  96	  
For	  example,	  the	  sensitivity	  of	  a	  dltA	  mutant	  strain	  of	  Lactobacillus	  casei	  BL23	  increased	  12.5-­‐97	  
fold	  for	  nisin,	  4.25-­‐fold	  for	  vancomycin,	  16-­‐fold	  for	  plectasin,	  4-­‐fold	  for	  mersacidin	  and	  2.5-­‐fold	  98	  
for	  subtilin,	  relative	  to	  the	  wild	  type	  strain	  (Revilla-­‐Guarinos	  et	  al.,	  2013).	  In	  turn,	  inactivation	  99	  
of	  MprF	  in	  Staphylococcus	  aureus	  Sa113	  resulted	  in	  a	  28-­‐fold	  increased	  sensitivity	  for	  nisin,	  7-­‐100	  
fold	   for	   gallidermin	   or	   12-­‐fold	   for	   protegrin	   3	   (Peschel	   et	   al.,	   2001).	   Both	   mechanisms	   are	  101	  
thought	  to	  reduce	  the	  net	  negative	  charge	  of	  the	  cell	  envelope,	  thus	  decreasing	  electrostatic	  102	  
interactions	  between	  CAMPs	  and	  the	  cell	   (Fig.	  2B).	  Recently,	  a	  second	  mode	  of	  action	  of	   the	  103	  
Dlt-­‐system	  was	   proposed,	   based	   on	   steric	   hindrance	   of	   CAMP	  passage	   through	   the	   cell	  wall	  104	  
due	  to	  an	  increased	  density	  of	  the	  peptidoglycan	  sacculus	  (Fig.	  2C)	  (Saar-­‐Dover	  et	  al.,	  2012).	  105	  
A	   further	  mechanism	  of	  CAMP	   resistance	   is	   by	   antibiotic-­‐specific	  ATP-­‐binding	   cassette	   (ABC)	  106	  
transporters	   (Fig.	   2),	  which	   are	   thought	   to	   remove	   the	   peptides	   from	   their	   site	   of	   action.	   A	  107	  
number	  of	  these	  transporters	  have	  been	  described.	  For	  example,	  the	  BceAB	  system	  of	  Bacillus	  108	  
subtilis	  confers	  resistance	  to	  bacitracin.	  A	  143-­‐fold	  increased	  sensitivity	  in	  B.	  subtilis	  168	  BceAB	  109	  
defective	   mutants	   has	   been	   reported	   (Ohki	   et	   al.,	   2003).	   Inactivation	   of	   the	   homologous	  110	  
system	  ABC	  09	  of	  L.	  casei	  BL23	  resulted	  in	  an	  increased	  sensitivity	  to	  bacitracin	  (2-­‐fold),	  nisin	  111	  
(1.7-­‐fold)	   plectasin	   (2-­‐fold)	   and	   subtilin	   (2.5-­‐fold)	   relative	   to	   the	   wild	   type	   strain	   (Revilla-­‐112	  
Guarinos	   et	   al.,	   2013).	   However,	   in	   contrast	   to	   canonical	   drug	   efflux	   systems	   for	   antibiotics	  113	  
that	  target	  intracellular	  structures,	  it	  is	  less	  obvious	  to	  envision	  how	  a	  transporter	  could	  impart	  114	  
efficient	  resistance	  against	  a	  drug	  that	  binds	  molecules	  located	  on	  the	  surface	  of	  the	  cell.	  For	  115	  
some	  CAMP	  transporters,	  a	  mechanism	  akin	  to	  the	  “hydrophobic	  vacuum	  cleaner”	  model	  has	  116	  
been	   proposed	   involving	   translocation	   of	   the	   peptide	   from	   the	   membrane	   to	   the	   culture	  117	  
supernatant	   (Stein	  et	  al.,	  2003;	  Stein	  et	  al.,	  2005;	  Okuda	  et	  al.,	  2008).	  The	  different	   types	  of	  118	  




CAMP	  resistance	  by	  D-­‐alanylation	  of	  teichoic	  acids:	  electrostatic	  or	  steric	  hindrance?	  121	  
The	  cell	  wall	  of	  Gram-­‐positive	  bacteria	  essentially	   consists	  of	   several	   layers	  of	  peptidoglycan	  122	  
interwoven	  with	  additional	  glycopolymers	  such	  as	  teichoic	  acids	  (Neuhaus	  and	  Baddiley,	  2003).	  123	  
Structure	  and	  function	  of	  teichoic	  acids	  has	  been	  the	  subject	  of	  a	  number	  of	  excellent	  reviews	  124	  
(Neuhaus	  and	  Baddiley,	  2003;	  Weidenmaier	  and	  Peschel,	  2008;	  Silhavy	  et	  al.,	  2010;	  Swoboda	  125	  
et	  al.,	  2010),	  and	  they	  will	  not	  be	  discussed	  in	  detail.	  Briefly,	  TAs	  are	  linear	  polymers	  typically	  126	  
constituted	   by	   monomers	   of	   glycerol-­‐P	   or	   ribitol-­‐P	   linked	   by	   phosphodiester	   bonds.	   These	  127	  
polymers	   can	   be	   attached	   to	   the	   peptidoglycan	   (wall	   teichoic	   acids,	   WTAs)	   by	   a	   glycosidic	  128	  
bridge	   or	   to	   the	   cell	   membrane	   (lipoteichoic	   acids,	   LTAs)	   via	   a	   glycolipid	   anchor	   (Fig.	   2A)	  129	  
(Neuhaus	   and	   Baddiley,	   2003).	   To	   this	   backbone,	   a	   number	   of	   substituents	   can	   be	   linked,	  130	  
among	  them	  D-­‐alanine,	  which	  can	  be	  coupled	  by	  an	  ester	  bond	  to	  free	  hydroxyl	  groups	  of	  the	  131	  
TA	   backbone	   or	   in	   some	   cases	   to	   glycosidic	   substituents	   (Wicken	   and	   Baddiley,	   1963;	  132	  
Sadovskaya	   et	   al.,	   2004;	   Sánchez	   Carballo	   et	   al.,	   2010).	   However,	   it	   must	   be	   noted	   that	   D-­‐133	  
alanylation	   is	   not	   a	   general	   characteristic	   of	   TAs,	   and	   it	   is	   apparently	   limited	   to	   Firmicutes	  134	  
(Neuhaus	  and	  Baddiley,	  2003).	  The	  degree	  of	  D-­‐alanylation	  is	  highly	  variable	  and	  depends	  on	  135	  
strain	   background	   and	   growth	   conditions	   (Perego	   et	   al.,	   1995;	  Neuhaus	   and	  Baddiley,	   2003;	  136	  
McCormick	  et	  al.,	  2011).	  137	  
The	   synthesis	   of	   D-­‐alanyl-­‐LTAs	   is	   accomplished	   by	   the	   concerted	   action	   of	   four	   proteins	  138	  
encoded	  by	  the	  dltABCD	  operon	  (Perego	  et	  al.,	  1995;	  Neuhaus	  et	  al.,	  1996).	  DltA	  catalyzes	  the	  139	  
synthesis	   of	   D-­‐alanyl-­‐AMP	   from	   D-­‐alanine	   and	   ATP	   and	   subsequently	   transfers	   this	  140	  
intermediary	  compound	  to	  the	  D-­‐alanyl	  carrier	  protein	  DltC	  ((Neuhaus	  and	  Baddiley,	  2003)	  and	  141	  
references	   therein).	   The	   role	   of	   proteins	   DltB	   and	   DltC	   remain	   to	   be	   determined.	   DltB	   is	  142	  
predicted	   to	   possess	   12	   membrane-­‐spanning	   domains	   (Neuhaus	   et	   al.,	   1996)	   and	   the	  143	  
hydropathy	  profile	  also	  predicts	  that	  DltD	  is	  anchored	  to	  the	  cell	  membrane	  by	  an	  N-­‐terminal	  144	  
hydrophobic	  domain	  (Debabov	  et	  al.,	  2000).	  145	  
7	  
	  
The	   regulation	   of	   dlt	   operon	   expression	   is	   operated	   by	   different	   mechanisms	   in	   different	  146	  
species,	  and	  usually	   it	   is	  subject	  to	  the	  control	  of	  several	  regulatory	  systems	  within	  the	  same	  147	  
organism.	  In	  Bacillus	  subtilis,	  dlt	  is	  part	  of	  the	  regulons	  of	  the	  extracytoplasmic-­‐function	  sigma	  148	  
factors	  σX	  (Cao	  and	  Helmann,	  2004;	  Kingston	  et	  al.,	  2013),	  σV	  (Guariglia-­‐Oropeza	  and	  Helmann,	  149	  
2011)	  and	  the	  two-­‐component	  system	  (TCS)	  YxdJK	  (Joseph	  et	  al.,	  2004).	   In	  staphylococci,	   the	  150	  
dlt	  operon	  is	  positively	  regulated	  by	  the	  TCS	  GraRS	  (Staphylococcus	  aureus;	  (Li	  et	  al.,	  2007b))	  or	  151	  
its	  homolog	  ApsRS	  (Staphylococcus	  epidermidis;	  (Li	  et	  al.,	  2007a))	  in	  response	  to	  CAMPs,	  and	  it	  152	  
is	  repressed	  by	  the	  TCS	  ArlRS	  in	  response	  to	  high	  extracellular	  concentrations	  of	  Mg2+,	  Ca2+	  or	  153	  
Na+	   (Koprivnjak	   et	   al.,	   2006).	   Furthermore,	   there	   is	   evidence	   indicating	   that	   the	   global	  154	  
regulators	  Agr	  (Dunman	  et	  al.,	  2001)	  and	  Rot	  (Saïd-­‐Salim	  et	  al.,	  2003)	  are	  also	   involved	   in	  dlt	  155	  
regulation	   in	   S.	   aureus.	   In	   Lactobacillus	   casei,	   TCS12	   regulates	   the	   expression	   of	   dlt,	   but	  156	  
induction	   of	   dlt	   expression	   in	   response	   to	   nisin	   was	   observed	   in	   TCS12-­‐defective	   mutants,	  157	  
indicating	   that	   additional	   regulatory	   mechanisms	   also	   operate	   in	   this	   organism	   (Revilla-­‐158	  
Guarinos	  et	  al.,	  2013).	  159	  
Studies	  of	  dlt	  mutants	  have	  shown	  that	  D-­‐alanylation	  of	  TAs	  has	  a	  wide	  range	  of	  physiological	  160	  
consequences	   in	   different	   bacteria	   as	   well	   as	   in	   their	   interactions	   with	   other	   organisms	  161	  
(Neuhaus	   and	   Baddiley,	   2003;	  Weidenmaier	   and	   Peschel,	   2008;	   Swoboda	   et	   al.,	   2010).	   This	  162	  
review	  will	  only	  focus	  on	  the	  important	  role	  of	  D-­‐alanylation	  for	  the	  resistance	  against	  CAMPs	  163	  
(Fig.	  2),	  as	  documented	  by	  numerous	  studies	  (Davie	  and	  Brock,	  1966;	  Peschel	  et	  al.,	  1999;	  Boyd	  164	  
et	  al.,	  2000;	  Abachin	  et	  al.,	  2002;	  Poyart	  et	  al.,	  2003;	  Kristian	  et	  al.,	  2005;	  Fabretti	  et	  al.,	  2006;	  165	  
Kovács	  et	  al.,	  2006;	  Saar-­‐Dover	  et	  al.,	  2012;	  Revilla-­‐Guarinos	  et	  al.,	  2013).	  These	  observations	  166	  
have	  been	  explained	  by	  postulating	  that	  D-­‐alanylation	  of	  TAs	  would	  diminish	  the	  electrostatic	  167	  
attraction	  between	  CAMPs	  and	   the	  cell	  envelope	  by	   reducing	   the	  net	  charge	  of	   the	  cell	  wall	  168	  
(Fig.	  2B)	  (Peschel	  et	  al.,	  1999;	  Neuhaus	  and	  Baddiley,	  2003;	  Peschel	  and	  Sahl,	  2006;	  Swoboda	  169	  
et	  al.,	  2010;	  Anaya-­‐López	  et	  al.,	  2013).	  This	  model	  is	  in	  accordance	  with	  different	  experimental	  170	  
observations	   demonstrating	   that	   a	   lack	   of	   alanylation	   leads	   to	   increased	   binding	   of	   several	  171	  
8	  
	  
positively	   charged	  molecules	   such	   as	  Mg2+	   (Heptinstall	   et	   al.,	   1970)	   or	   cytochrome	   c	   (Cyt	   c)	  172	  
(Wecke	  et	  al.,	  1997;	  Peschel	  et	  al.,	  1999;	  Kristian	  et	  al.,	  2005;	  Saar-­‐Dover	  et	  al.,	  2012;	  Revilla-­‐173	  
Guarinos	  et	  al.,	  2013)	  and	  also	   the	  CAMPs	  gallidermin	   (Peschel	  et	  al.,	  1999)	  and	  vancomycin	  174	  
(Peschel	  et	  al.,	  2000).	  175	  
While	   this	   model	   (Fig.	   2B)	   is	   generally	   accepted,	   a	   number	   of	   recent	   observations	   have	  176	  
challenged	  it.	  A	  dltA	  mutant	  of	  Streptococcus	  agalactiae	  was	  shown	  to	  bind	  three	  times	  more	  177	  
Cyt	  c	  than	  the	  wild-­‐type	  strain.	  However,	  no	  significant	  differences	  in	  binding	  of	  a	  number	  of	  178	  
CAMPs	  were	  detected,	   indicating	   that	  different	   interactions	  account	   for	   the	  binding	  of	  Cyt	  c	  179	  
and	   the	   binding	   of	   CAMPs	   (Saar-­‐Dover	   et	   al.,	   2012).	   A	   direct	   estimation	   of	   the	   net	   electric	  180	  
charge	   of	   Lactococcus	   lactis	   cells	   by	   electrophoretic	   mobility	   measurements	   detected	   no	  181	  
significant	   difference	   in	   global	   cell	   charge	  between	   the	  wild-­‐type	   strain	   and	   a	  dltD-­‐defective	  182	  
mutant	   (Giaouris	   et	   al.,	   2008).	   This	   observation	   is	   in	   accordance	   with	   results	   from	   similar	  183	  
experiments	   on	   L.	   casei	   in	   our	   own	   laboratory	   (unpublished	   results).	   The	   estimation	   of	   cell	  184	  
electric	  charge	  by	  binding	  assays	  relies	  on	  the	  assumption	  that	  the	  interaction	  between	  the	  cell	  185	  
envelope	   and	   the	   ligand	   is	   essentially	   electrostatic	   and	   independent	   of	   the	   nature	   of	   the	  186	  
ligand.	   However,	   the	   contribution	   of	   other	   interactions	   should	   be	   taken	   into	   account.	   For	  187	  
example,	   hydrophobic	   interactions	   between	   Cyt	   c	   and	   cell	   membrane	   lipids	   have	   been	  188	  
observed	  earlier	   (Rytömaa	  et	  al.,	  1992;	  Cortese	  et	  al.,	  1995)	  and	  might	   influence	  the	  binding	  189	  
affinity	  for	  Cyt	  c	  of	  the	  bacterial	  cell	  envelope.	  190	  
Based	   on	   these	   and	   the	   following	   observations,	   an	   alternative	  model	   (Fig.	   2C)	   was	   recently	  191	  
proposed	   that	   suggests	   that	  D-­‐alanylation	  of	  TAs	   leads	   to	  structural	  modifications	  of	   the	  cell	  192	  
wall	  making	  it	  more	  compact	  and	  less	  permeable	  and	  hence	  restricting	  the	  access	  of	  CAMPs	  to	  193	  
the	  membrane	  (Saar-­‐Dover	  et	  al.,	  2012).	  In	  support,	  these	  authors	  showed	  that	  the	  cell	  wall	  of	  194	  
a	  S.	  agalactiae	  dltA	  mutant	  is	  less	  dense	  and	  its	  surface	  is	  less	  rigid	  than	  that	  of	  the	  wild-­‐type	  195	  
strain.	  It	  was	  shown	  that	  binding	  of	  CAMPs	  to	  LTA	  was	  not	  significantly	  different	  between	  the	  196	  
two	  strains;	  however,	  access	  of	  CAMPs	  to	  the	  membrane	  was	  increased	  in	  the	  dltA-­‐defective	  197	  
9	  
	  
mutant.	   Furthermore,	   the	   authors	   observed	   that	   high	   NaCl	   concentration	   reduced	   the	  198	  
penetration	  of	  CAMPs	  through	  the	  cell	  wall	  of	  the	  dltA	  strain	  to	  restore	  wild-­‐type	  behaviour.	  	  199	  
Previous	   studies	   had	   already	   noted	   alterations	   in	   the	   cell	   wall	   structure	   in	   response	   to	   the	  200	  
extent	  of	  D-­‐alanylation	  of	  TAs.	  Ou	  and	  Marquis	  observed	  that	  removal	  of	  D-­‐alanyl	  esters	  from	  201	  
TAs	  of	  S.	  aureus	  caused	  an	  expansion	  of	  the	  cell	  wall	  (Ou	  and	  Marquis,	  1970).	  Furthermore,	  it	  is	  202	  
well	  established	  that	  TAs	  play	  a	  major	  role	   in	  the	  structure	  of	  the	  cell	  wall	  and	  that	  the	  ionic	  203	  
environment	  is	  a	  determinant	  in	  the	  structural	  transitions	  of	  TAs	  (Doyle	  et	  al.,	  1974;	  Pal	  et	  al.,	  204	  
1990).	   Incorporation	  of	  D-­‐alanyl	   residues	   in	  TAs	  would	  change	  the	   ionic	  environment	  around	  205	  
TAs,	  thus	  modulating	  the	  conformational	  transitions	  of	  TAs	  (Neuhaus	  and	  Baddiley,	  2003;	  Saar-­‐206	  
Dover	   et	   al.,	   2012).	   These	   transitions	   could	   account	   for	   the	   structural	   differences	   observed	  207	  
between	  the	  cell	  walls	  of	  D-­‐alanyl-­‐TAs	  deficient	  strains	  and	  those	  of	  the	  parental	  strains.	  Taken	  208	  
together,	   this	   evidence	   supports	   the	   idea	   that	   D-­‐alanylation	   of	   teichoic	   acids	   modifies	   the	  209	  
electrostatic	   interactions	   between	   TAs	   leading	   to	   a	   strengthening	   of	   the	   cell	   wall	   and	   an	  210	  
increase	   of	   its	   barrier	   properties	   (Fig.	   2C).	   This	   would	   impede	   the	   access	   of	   the	   usually	  211	  
amphipathic	  CAMPs	  to	  the	  membrane.	  212	  
	  213	  
CAMP	  resistance	  by	  ABC	  transporter-­‐mediated	  antibiotic	  removal	  214	  
Recently,	  a	  classification	  scheme	  for	  ABC	  transporters	  involved	  in	  the	  removal	  of	  CAMPs	  from	  215	  
the	   cell	   membrane	   of	   Firmicutes	   based	   on	   their	   predicted	   domain	   architectures	   has	   been	  216	  
proposed	   (Gebhard,	   2012),	   which	   was	   in	   accordance	   with	   functional	   characteristics	   such	   as	  217	  
transport	  mechanism	  and	   regulation.	  ABC	   transporters	  were	   classified	   into	   five	  groups,	  each	  218	  
named	   after	   one	   well-­‐characterized	   example	   as	   SunT-­‐type,	   NisT-­‐type,	   LanFEG-­‐type,	   BceAB-­‐219	  
type	   and	   BcrAB-­‐type	   transporters.	   The	   first	   two	   groups	   are	   involved	   in	   the	   export	   of	   newly	  220	  
synthetized	   CAMPs	   and	   will	   not	   be	   considered	   further	   here.	   The	   other	   three	   groups	   of	  221	  
transporters	   will	   be	   described	   in	   the	   following	   section,	   highlighting	   the	   most	   striking	  222	  
mechanistic	   aspects	   of	   AMP	   resistance	   of	   each	   group,	   and	   a	   summary	   of	   their	   main	  223	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characteristics	   is	   presented	   in	   Table	   1.	   For	   reasons	   of	   conciseness,	   only	   some	   supporting	  224	  
relevant	  examples	  will	  be	  discussed.	  Readers	  are	   referred	   to	  a	   recent	  comprehensive	   review	  225	  
for	  further	  information	  (Gebhard,	  2012).	  226	  
Among	   the	   resistance	   transporters	   two	   mechanisms	   of	   CAMP	   detoxification	   can	   be	  227	  
distinguished	  (Fig.	  3).	  For	  LanFEG	  and	  BcrAB-­‐type	  transporters,	  the	  transporter	  is	  sufficient	  for	  228	  
partial	  resistance	  but	  additional	  proteins	  help	  to	  provide	  full	  protection	  from	  AMPs.	  In	  the	  case	  229	  
of	  the	  BceAB-­‐group,	  the	  transporter	  plays	  a	  role	  in	  sensing,	  signaling	  and	  detoxification	  of	  the	  230	  
AMPs.	  231	  
	  232	  
LanFEG	  and	  BcrAB	  type	  transporters:	  playing	  with	  partners	  for	  higher	  resistance	  233	  
Most	   LanFEG-­‐type	   transporters	  are	   involved	   in	   self-­‐protection	   in	   lantibiotic	  producer	   strains,	  234	  
and	  recognize	  only	  a	  narrow	  range	  of	  related	  substrates	  (Otto	  et	  al.,	  1998;	  Stein	  et	  al.,	  2003;	  235	  
Gebhard,	   2012).	   BcrAB	   transporters	   mediate	   resistance	   against	   bacitracin	   (Podlesek	   et	   al.,	  236	  
1995;	  Neumüller	  et	  al.,	  2001).	  LanFEG	  and	  BcrAB	  transporters	  are	  composed	  of	  two	  permease	  237	  
subunits	  with	   six	   predicted	   transmembrane	   helices,	  which	   can	   be	   encoded	   by	   two	   separate	  238	  
genes	   (lanE	   and	   lanG	   in	   LanFEG-­‐type)	   or	   a	   single	   gene	   (bcrB	   in	   BcrAB-­‐type).	   The	   ATPase	  239	  
subunits	   are	   encoded	   by	   separate	   genes	   in	   both	   types	   of	   transporters	   (lanF	   and	   bcrA,	  240	  
respectively)	   (Gebhard,	  2012).	  Phylogenetic	  analyses	  have	  shown	  that	  BcrAB	  and	  LanFEG	  are	  241	  
closely	  related,	  and	  they	  also	  share	  functional	  characteristics	  (Gebhard,	  2012).	  Several	  studies	  242	  
reported	   that	   these	   transporters	   remove	   lantibiotics	   from	   the	   cytoplasmic	   membrane	   and	  243	  
discharge	  them	  to	  the	  extracellular	  medium	  (Stein	  et	  al.,	  2003;	  Stein	  et	  al.,	  2005;	  Okuda	  et	  al.,	  244	  
2008)	   (Fig.	   3A,	   step	   3).	   It	   remains	   unclear,	   however,	   how	   cells	   prevent	   CAMPs	   from	  binding	  245	  
again	   to	   the	   cytoplasmic	   membrane.	   In	   this	   regard,	   the	   high	   degree	   of	   co-­‐occurrence	   of	  246	  
LanFEG-­‐type	   transporters	   with	   LanI	   or	   LanH	   immunity	   proteins	   (78%),	   and	   of	   BcrAB-­‐type	  247	  
transporters	   with	   UppP	   (undecaprenyl	   pyrophosphate	   phosphatase)-­‐encoding	   genes	   (77%)	  248	  
should	   be	   noted	   (Gebhard,	   2012).	   To	   date,	   conflicting	   data	   is	   reported	   on	   whether	  249	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transporters	  and	  immunity	  proteins	  act	  cooperatively	  or	  independently	  of	  each	  other	  to	  confer	  250	  
resistance.	   An	   independent	   action	   has	   been	   proposed	   for	   the	   nisin	   resistance	   system	   of	  251	  
Lactococcus	   lactis,	   constituted	  by	   the	   immunity	  protein	  NisI	   and	   the	   transporter	  NisFEG	   and	  252	  
for	  the	  SpaI-­‐SpaFEG	  system	  of	  Bacillus	  subtilis,	  which	  provides	  self-­‐protection	  against	  subtilin	  253	  
(Stein	  et	  al.,	  2003;	  Stein	  et	  al.,	  2005).	  Other	  studies	  suggested	  cooperativity	  between	  NisI	  and	  254	  
NisFEG	   (Ra	  et	  al.,	   1999;	  Takala	  et	  al.,	   2004;	  Takala	  and	  Saris,	  2006),	  or	  between	   the	  nukacin	  255	  
ISK-­‐1	   immunity	  protein	  NukH	  and	  NukFEG	   (Okuda	  et	  al.,	  2008).	   It	   is	  attractive	   to	  postulate	  a	  256	  
concerted	  action	  of	  transporters	  and	  immunity	  proteins,	  which	  might	  explain	  the	  mechanism	  257	  
of	   resistance:	   the	   transporter	   would	   remove	   cell	   membrane-­‐associated	   CAMPs	   and	   release	  258	  
them	   to	   the	   external	  media	  while	   immunity	   proteins	  would	   bind	   and	   sequester	   the	   CAMPs,	  259	  
thus	  avoiding	   re-­‐association	  with	   the	  bacterial	   surface	   (Fig.	   3A,	   steps	  1	  and	  2)	   (Takala	  et	   al.,	  260	  
2004).	  261	  
BcrAB-­‐type	  transporters	  are	  often	  encoded	  in	  an	  operon	  with	  a	  UppP	  encoding	  gene	  (Gebhard,	  262	  
2012).	   It	   is	   therefore	   likely	   that	   the	   bacitracin	   resistance	   mechanism	   of	   the	   transporter	   is	  263	  
tightly	  linked	  to	  UppP	  activity	  (Fig.	  3A,	  steps	  3	  and	  4).	  In	  fact,	  it	  has	  been	  shown	  that	  increasing	  264	  
UppP	   activity	   confers	   increased	   resistance	   to	   bacitracin	   (Bernard	   et	   al.,	   2005;	   Shaaly	   et	   al.,	  265	  
2013),	  whereas	  its	  inactivation	  led	  to	  increased	  sensitivity	  (Cao	  and	  Helmann,	  2002;	  Shaaly	  et	  266	  
al.,	   2013).	   Therefore,	  maximal	  protection	   is	  most	   likely	   ensured	  when	   transporter	   and	  UppP	  267	  
act	  concertedly	  (Podlesek	  et	  al.,	  1995).	  268	  
The	   efflux	   mechanism	   used	   by	   these	   transporters	   still	   awaits	   elucidation	   although	   the	  269	  
hydrophobic	   vacuum-­‐cleaner	  model,	   originally	   proposed	   for	   the	   eukaryotic	   P-­‐glycoprotein,	   a	  270	  
multidrug	  ABC	  transporter	  (Raviv	  et	  al.,	  1990),	  currently	  receives	  major	  acceptance.	  This	  model	  271	  
hypothesizes	  that	  the	  target	  compounds	  enter	  the	  transporter	  binding	  sites	  directly	  from	  the	  272	  
membrane	   and	   are	   released	   to	   the	   extracellular	  medium.	   Subsequent	   studies	   demonstrated	  273	  
that	   the	   P-­‐glycoprotein	   binds	   its	   substrates	   within	   the	   inner	   leaflet	   of	   the	   membrane	   and	  274	  
releases	   them	   to	   the	   extracellular	  medium	   (Shapiro	   et	   al.,	   1997;	   Shapiro	   and	   Ling,	   1998)	   as	  275	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postulated	  by	   the	  hydrophobic	   vacuum	  cleaner	  model.	   In	   the	   same	  way,	   transport	   from	   the	  276	  
inner	   leaflet	   to	   the	   extracellular	   medium	   was	   demonstrated	   for	   the	   L.	   lactis	   multidrug	  277	  
resistance	  ABC	  transporter	  LmrA	  (Bolhuis	  et	  al.,	  1996).	  However,	  it	  remains	  to	  be	  seen	  if	  such	  a	  278	  
mechanism	   is	  directly	  applicable	   to	   the	  CAMP	  transporters	  discussed	  here,	  whose	  substrates	  279	  
are	  most	  likely	  located	  in	  the	  outer	  leaflet	  of	  the	  membrane.	  280	  
	  281	  
BceAB-­‐type	   transporters:	   sensors,	   triggers	  and	  detoxification	  pumps	  with	  a	  broad	   range	  of	  282	  
substrates	  283	  
BceAB-­‐type	   transporters	   mediate	   resistance	   to	   CAMPs	   but	   are	   usually	   not	   associated	   with	  284	  
biosynthetic	   loci.	   In	   contrast	   to	   BcrAB	   and	   most	   LanFEG-­‐type	   transporters,	   BceAB-­‐type	  285	  
transporters	   display	   a	   broader	   substrate	   range	  but	   can	   also	   distinguish	   between	   structurally	  286	  
similar	  substrates	  (Table	  1)	  (Gebhard	  and	  Mascher,	  2011;	  Gebhard,	  2012).	  For	  example,	  the	  B.	  287	  
subtilis	   PsdAB	   transporter	   is	   able	   to	   transport	   the	   lantibiotic	   actagardine	  but	   not	   the	   similar	  288	  
one	  mersacidin.	  At	  the	  same	  time,	  PsdAB	  also	  transports	  the	  lipodepsipeptide	  enduracidin	  but	  289	  
not	  the	  structurally	  similar	  ramoplanin	  (Staroń	  et	  al.,	  2011).	  The	  molecular	  mechanism	  behind	  290	  
this	  characteristic	  is	  still	  unclear.	  291	  
The	   most	   noticeable	   feature	   of	   BceAB-­‐type	   transporters	   is	   their	   frequent	   genetic	   and	  292	  
functional	   association	   with	   BceRS-­‐type	   TCS	   (Fig.	   3B)	   (Joseph	   et	   al.,	   2002;	   Mascher,	   2006;	  293	  
Dintner	   et	   al.,	   2011).	   A	   phylogenetic	   analysis	   demonstrated	   the	   coevolution	   of	   these	  294	  
transporters	   and	  TCS	   in	   Firmicutes,	   supporting	   the	   functional	   link	  between	   them	   (Dintner	  et	  295	  
al.,	  2011).	  These	  Bce-­‐like	  modules,	  named	  after	  the	  bacitracin	  resistance	  module	  BceRSAB	  of	  296	  
Bacillus	   subtilis	   (Mascher	   et	   al.,	   2003;	   Ohki	   et	   al.,	   2003),	   are	   antimicrobial	   peptide	  297	  
detoxification	   systems	   in	   which	   the	   transporter	   plays	   a	   dual	   role:	   it	   mediates	   AMP	  298	  
resistance/detoxification	   and	   is	   also	   required	   for	   AMP	   sensing	   (Rietkötter	   et	   al.,	   2008).	   The	  299	  
ABC	   transporter	   BceAB	   detects	   the	   stimulus,	   i.e.	   presence	   of	   bacitracin,	   and	   transfers	   the	  300	  
signal	  to	  the	  histidine	  kinase	  (HK)	  BceS,	  which	  does	  not	  function	  as	  a	  direct	  sensor	  but	  rather	  301	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as	  a	  signal	  transfer	  relay	  to	  BceR.	  Activation	  of	  the	  response	  regulator	  BceR	  then	  induces	  the	  302	  
expression	   of	   bceAB	   and	   thus	   ensures	   resistance.	   Experimental	   evidence	   from	   a	   number	   of	  303	  
homologous	   systems	   from	   B.	   subtilis,	   Staphylococcus	   aureus,	   Streptococcus	   mutans,	   and	  304	  
Lactobacillus	  casei	  has	  confirmed	  such	  a	  signaling	  pathway	  as	  a	  general	  characteristic	  of	  Bce-­‐305	  
type	  modules	   (Rietkötter	   et	   al.,	   2008;	   Ouyang	   et	   al.,	   2010;	   Hiron	   et	   al.,	   2011;	   Staroń	   et	   al.,	  306	  
2011;	   Falord	   et	   al.,	   2012;	   Revilla-­‐Guarinos	   et	   al.,	   2013).	   Interestingly,	   some	   BceAB-­‐like	  307	  
transporters	  appear	   to	  have	  developed	  specified	   functions.	  While	  some	  display	   the	  dual	   role	  308	  
described	  above,	  others	  function	  only	  as	  a	  sensor	  or	  only	  as	  a	  resistance	  pump	  (Fig.	  3B).	  In	  the	  309	  
latter	   case,	   two	   transporters	   and	   one	   TCS	   are	   required	   to	   constitute	   a	   functional	   Bce-­‐like	  310	  
module,	  as	  will	  be	  described	  in	  the	  following	  paragraphs.	  311	  
Sensing	  transporters	  (Fig.	  3B,	  model	  5)	  detect	  the	  presence	  of	  a	  CAMP	  and	  transfer	  the	  signal	  312	  
to	   their	   cognate	   HKs	   but	   do	   not	   confer	   resistance.	   However,	   it	   is	   worth	   noting	   that	   ATP	  313	  
hydrolysis	  by	  the	  transporter	  is	  still	  required	  for	  the	  signaling	  process	  (Rietkötter	  et	  al.,	  2008;	  314	  
Hiron	  et	  al.,	  2011).	  It	  has	  been	  suggested	  that	  transport	  by	  these	  transporters	  takes	  place	  at	  a	  315	  
low	  rate	  that	  is	  enough	  for	  signaling	  the	  presence	  of	  the	  antibiotic	  to	  the	  partner	  HK,	  but	  not	  316	  
sufficient	  for	  conferring	  resistance	  to	  it	  (Gebhard	  and	  Mascher,	  2011).	  A	  characteristic	  feature	  317	  
of	  Bce-­‐like	  modules	  harbouring	  a	  sensing	  ABC	  is	  that	  they	  usually	  control	  an	  extended	  regulon	  318	  
that	   includes	  ABC	  transporters	  (the	  sensing	  and/or	  associated	  resistance	  transporters),	  genes	  319	  
involved	   in	   the	   cell	   envelope	   stress	   response	   like	  dltABCD	   and	  mprF	  and	   genes	   for	   cell	  wall	  320	  
biosynthesis	   (Fig.	   3B,	   model	   5).	   In	   the	   Aps/GraRS-­‐VraFG	   system,	   VraFG	   is	   the	   sensing	  321	  
transporter,	   and	   resistance	   involves	   expression	   of	   the	  dlt-­‐operon	   and	  mprF,	   which	   together	  322	  
with	  VraFG	  are	  under	  transcriptional	  control	  of	  the	  TCS	  Aps/GraRS	  (Li	  et	  al.,	  2007b;	  Meehl	  et	  323	  
al.,	  2007;	  Falord	  et	  al.,	  2011;	  Falord	  et	  al.,	  2012).	  Another	  complex	  Bce-­‐like	  regulatory	  network	  324	  
of	  AMP	  detoxification	  modules	  was	  recently	  described	  in	  L.	  casei	  BL23	  (Revilla-­‐Guarinos	  et	  al.,	  325	  
2013).	   Module	   12	   of	   this	   strain	   was	   shown	   to	   be	   a	   sensory	   system	   controlling	   CAMPs	  326	  
resistance.	   ABC12	   is	   the	   sensory	   transporter	   that	   communicates	   with	   TCS12,	   which	   in	   turn	  327	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ensures	   the	   expression	   of	   dltABCD,	   mprF,	   and	   an	   additional	   “orphan”	   BceAB-­‐type	   ABC	  328	  
transporter	  that	  is	  located	  in	  a	  different	  position	  of	  the	  chromosome.	  329	  
Dedicated	   resistance	   transporters	   (Fig.	   3B,	   model	   6)	   mediate	   the	   actual	   resistance	   to	   the	  330	  
antibiotic,	  but	  are	  not	  involved	  in	  peptide	  sensing	  and	  signaling.	  They	  are	  usually	  controlled	  by	  331	  
a	  not	  genetically	  associated	  BceRS-­‐type	  TCS,	  which	  is	  typically	  encoded	  together	  with	  a	  sensory	  332	  
transporter.	   A	   characterized	   example	   is	   the	   VraDE	   transporter	   of	   S.	   aureus,	   which	  mediates	  333	  
resistance	  to	  CAMPs	  and	  is	  under	  control	  of	  the	  BraRSDE	  module,	  where	  BraRS	  is	  the	  TCS	  and	  334	  
BraDE	  the	  sensory	  transporter	  (Hiron	  et	  al.,	  2011).	  335	  
The	  third	  group	  of	  BceAB-­‐type	  systems	  consists	  of	  ABC	  transporters	  with	  a	  dual	  function:	  they	  336	  
are	   involved	   in	  substrate	  sensing	  and	  signaling	  and	  also	  confer	   resistance	   to	   it.	  Hence,	   these	  337	  
transporters	   regulate	   their	   own	   expression	   in	   response	   to	   AMPs	   via	   BceRS-­‐like	   TCS	   (Fig.	   3B,	  338	  
model	   7)	   (Rietkötter	   et	   al.,	   2008).	   Once	   the	   inducing	   compound	   is	   removed,	   the	   system	  339	  
switches	  off.	  An	  example	  of	  these	  systems	  is	  module	  09	  of	  L.	  casei.	  ABC09	  mediates	  resistance	  340	  
to	   bacitracin,	   nisin,	   plectasin,	   and	   subtilin	   (Revilla-­‐Guarinos	   et	   al.,	   2013).	   Its	   expression	   is	  341	  
induced	   in	   a	   concentration	   dependent	   manner	   by	   nisin	   through	   the	   cognate	   TCS09,	   which	  342	  
depends	   on	   ABC09	   for	   its	   activation.	   Accordingly,	   module	   09	   is	   a	   stand-­‐alone	   resistance	  343	  
module	  where	  ABC09	  senses	   the	   target	  CAMPs	  and	   transfer	   the	  signal	   to	  TCS09,	   resulting	   in	  344	  
the	  induction	  of	  the	  expression	  of	  ABC09,	  which	  confers	  the	  resistance	  (Revilla-­‐Guarinos	  et	  al.,	  345	  
2013).	   The	   same	   is	   true	   for	   at	   least	   two	   out	   of	   the	   three	   B.	   subtilis	   Bce-­‐type	   resistance	  346	  
modules,	  which	  also	  possess	  transporters	  with	  a	  dual	  function.	  BceRSAB	  is	  the	  most	  effective	  347	  
bacitracin	   resistance	   system	   (Mascher	   et	   al.,	   2003;	   Ohki	   et	   al.,	   2003),	   but	   it	   also	   confers	  348	  
resistance	   to	   mersacidin,	   actagardine	   and	   plectasin	   (Staroń	   et	   al.,	   2011).	   The	   paralogous	  349	  
system	  PsdRSAB	  is	   induced	  by	  enduracidin,	  actagardine,	  gallidermin,	  nisin	  and	  subtilin,	  and	  it	  350	  
mediates	   resistance	   to	   all	   of	   its	   inducers	   excepting	   actagardine	   (Staroń	   et	   al.,	   2011).	   Both	  351	  
systems	  are	  stand-­‐alone	  detoxification	  modules	  (Ohki	  et	  al.,	  2003;	  Rietkötter	  et	  al.,	  2008;	  Staroń	  352	  
et	  al.,	  2011).	  353	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Although	  the	  role	  of	  Bce-­‐type	  resistance	  modules	   in	   the	  regulation	  of	   transcription	  has	  been	  354	  
thoroughly	   studied,	   details	   of	   the	  mechanism	   of	   transport	   and	   signal	   transduction	   have	   not	  355	  
been	  completely	  determined.	  356	  
	  357	  
Open	  questions	  and	  concluding	  remarks	  358	  
Significant	   progress	   has	   been	  made	   in	   the	   last	   years	   to	   understand	   the	  major	   systems	   that	  359	  
confer	  CAMP	   resistance	   in	   Firmicutes,	   both	  with	   regard	   to	   the	   role	  of	  D-­‐alanylation	   and	   the	  360	  
function	   of	   designated	   ABC	   transporters.	   Nevertheless,	   the	   studies	   summarized	   above	   have	  361	  
also	   led	   to	   a	   number	   of	   open	   questions	   that	   still	   need	   to	   be	   addressed	   in	   order	   to	   provide	  362	  
mechanistic	  insights	  into	  how	  those	  systems	  work.	  363	  
The	   identification	   of	   a	   potential	   second	   mechanism	   by	   which	   D-­‐alanylation	   of	   TAs	   affects	  364	  
CAMP	  sensitivity	  raises	  the	  question,	  whether	  electrostatic	  and	  steric	  hindrance	  are	  mutually	  365	  
exclusive	  concepts	  or	  whether	  both	  contribute	   to	  CAMP	  resistance	   (Fig.	  2).	  The	  evidence	   for	  366	  
both	  mechanisms	  argues	  in	  favor	  of	  the	  latter,	  but	  further	  studies	  will	  be	  necessary	  to	  answer	  367	  
these	  questions.	  368	  
In	  the	  transporter-­‐mediated	  resistance,	  both	  the	  mechanism	  of	  substrate	  binding	  and,	   in	  the	  369	  
case	  of	  BceAB-­‐like	  systems,	  the	  direction	  of	  transport	  have	  not	  been	  determined	  so	  far	  (Table	  370	  
1).	   BceB-­‐like	   permeases	   are	  membrane	   proteins	   with	   ten	   predicted	   transmembrane	   helices	  371	  
and	   a	   large	   extracytoplasmic	   domain	   (ECD)	   of	   approximately	   200	   amino	   acids.	   While	  372	  
phylogenetic	   analyses	   of	   the	   transmembrane	   regions	   of	   BceB-­‐like	   transport	   permeases	  373	  
showed	  good	  sequence	  conservation	  at	  the	  amino	  acid	  level,	  the	  ECD	  regions	  did	  not	  (Dintner	  374	  
et	  al.,	  2011).	  This	  high	  degree	  of	  variability	  of	  the	  ECD	  agrees	  with	  the	  proposal	  that	  this	  region	  375	  
of	   the	  permease	   contains	   the	   substrate	  binding	  domain	  of	   the	   transporter	   (Rietkötter	  et	   al.,	  376	  
2008),	  and	  that	  the	  high	  degree	  of	  variability	  reflects	  the	  wide	  range	  of	  CAMPs	  to	  which	  they	  377	  
confer	   resistance	   (Dintner	   et	   al.,	   2011).	   Some	   experimental	   results	   support	   this	   idea.	   The	   S.	  378	  
aureus	   ABC	   transporter	   VraDE	   confers	   bacitracin	   resistance	   while	   VraFG	   is	   involved	   in	  379	  
16	  
	  
resistance	   to	   colistin.	   Domain-­‐swapping	   studies	   showed	   that	   a	   transporter	   with	   a	   chimeric	  380	  
VraG	   permease	   harbouring	   the	   ECD	   of	   VraE,	   vraFG*vraE,	   restored	   bacitracin	   resistance	   in	   a	  381	  
ΔvraDE	  mutant	  but	  was	  not	  able	  to	  restore	  colistin	  resistance	  in	  a	  ΔvraFG	  mutant	  strain	  (Hiron	  382	  
et	  al.,	  2011).	  383	  
Moreover,	   the	   exact	   molecular	   mechanism	   by	   means	   of	   which	   the	   signal	   information	   is	  384	  
transferred	   from	  the	  transporter	   to	   the	  HK	   is	  also	  not	  known	  yet.	   It	  has	  been	  proposed	   that	  385	  
BceAB-­‐type	  transporters	  might	  function	  as	  importers	  so	  that	  detection	  by	  the	  cognate	  HKs	  and	  386	  
CAMP	   inactivation	  would	  occur	   in	   the	   cytoplasm	   (Rietkötter	  et	   al.,	   2008;	  Hiron	  et	   al.,	   2011).	  387	  
However,	  the	  identification	  of	  mutations	  in	  BceB	  that	  significantly	  decreased	  signaling	  activity	  388	  
while	  retaining	  bacitracin	  resistance	  seems	  to	  rule	  out	  this	  hypothesis,	  at	  least	  for	  the	  BceRSAB	  389	  
module	  (Kallenberg	  et	  al.,	  2013).	  A	  second	  hypothesis	  postulates	  that	  the	  transporter	  binds	  the	  390	  
substrate	  and	  presents	   it	   to	   the	  HK,	  which	  would	   then	  only	   recognize	   it	   in	  complex	  with	   the	  391	  
transporter	  (Schrecke	  et	  al.,	  2012).	  In	  this	  case	  signal	  detection	  by	  the	  HK	  might	  occur	  through	  392	  
the	   short	  extracytoplasmatic	   loop	  of	   the	  HK.	  This	   idea	   is	   supported	  by	   results	  obtained	  with	  393	  
the	  homologous	  HKs	  GraS	  of	  S.	  aureus	  and	  ApsS	  of	  S.	  epidermidis.	  These	  two	  proteins	  show	  an	  394	  
overall	   70%	   similarity,	  which	   is	   reduced	   to	   33%	   for	   the	   extracellular	   loop.	   ApsS	   responds	   to	  395	  
hBD3	  whereas	  GraS	  does	  not.	  However,	  a	  hybrid	  GraS	  with	  the	  ApsS	  extracellular	  loop	  responds	  396	  
to	   hBD3	   (Li	   et	   al.,	   2007b).	   But	   this	   hypothesis	   does	   not	   explain	   why	   ATP	   hydrolysis	   by	   the	  397	  
transporter	  is	  required	  for	  signal	  transfer,	  since	  substrate	  binding	  should	  be	  ATP-­‐independent.	  398	  
The	   third	   hypothesis	   postulates	   that	   signal	   transfer	   occurs	   by	   direct	   protein-­‐protein	   contact	  399	  
between	  the	  ABC	  transporter	  and	  the	  HK,	  where	  a	  conformational	  change	   in	  the	  transporter	  400	  
due	  to	  substrate	  binding	  and	  transport	  could	  activate	  the	  HK.	  This	  hypothesis	  is	  supported	  by	  401	  
results	  obtained	  by	  two-­‐hybrid	  assays	  carried	  out	  with	  the	  GraXSR-­‐VraFG	  system	  of	  S.	  aureus	  402	  
(Falord	   et	   al.,	   2012)	   and	   the	   BceRSAB	   of	  B.	   subtilis	   (Kallenberg	   et	   al.,	   2013)	  which	   revealed	  403	  
interactions	  between	  HKs	  and	  cognate	  ABC	  transporters.	  404	  
17	  
	  
Different	  strategies	  for	  CAMP	  resistance	  in	  Firmicutes	  have	  been	  reviewed	  in	  this	  work,	  which,	  405	  
while	  being	  very	  distinct	  from	  one	  another,	  all	  serve	  the	  same	  purpose:	  to	  enhance	  bacterial	  406	  
survival	   in	   competitive	   environments.	   The	   recently	   proposed	   electrostatic-­‐steric	   hindrance	  407	  
model	   for	   the	  Dlt-­‐mediated	   resistance	   as	  well	   as	   the	  many	  unanswered	  questions	   regarding	  408	  
ABC	   transporters,	   highlight	   the	   complexity	   of	   this	   subject.	   Given	   the	   significant	   amount	   of	  409	  
progress	   made	   in	   recent	   years	   and	   the	   diversity	   of	   different	   organisms	   and	   experimental	  410	  
approaches	   currently	   applied	   to	   study	   both	   mechanisms	   of	   CAMP	   resistance,	   one	   can	   be	  411	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Figure	  legends	  688	  
Fig.	   1.	   A.	   Structural	   and	   compositional	   diversity	   of	   antimicrobial	   peptides.	   Schematic	  689	  
representations	   of	   the	   structures	   of	   nisin,	   bacitracin,	   ramoplanin	   and	   protegrin.	   The	   amino	  690	  
acids	  are	  represented	  by	  labeled	  gray	  circles.	  Positively	  and	  negatively	  charged	  amino	  acids	  at	  691	  
neutral	   pH	   are	   highlighted	   in	   red	   and	  white,	   respectively.	   Abu,	   aminobutyric	   acid;	   Chp,	   L-­‐3-­‐692	  
chloro-­‐4-­‐hydroxyphenylglycine;	   Dha,	   didehydroalanine;	   Dhb,	   didehydrobutyrine;	   HAsn,	   β-­‐693	  
hydroxyasparagine;	   D-­‐Hpg,	   D-­‐hydroxyphenylglycine;	   L-­‐Hpg,	   L-­‐hydroxyphenylglycine;	   Man,	  694	  
mannose;	  Orn,	  D-­‐ornithine;	  aThr,	  D-­‐allo-­‐threonine.	  695	  
B.	  Schematic	  representation	  of	  peptidoglycan	  biosynthesis	  and	  its	  inhibition	  by	  CAMPs.	  696	  
Important	  steps	  in	  cell	  wall	  biosynthesis	  are	  depicted,	  and	  their	  cellular	  location	  is	  indicated	  	  697	  
on	  the	  left.	  CW,	  cell	  wall;	  CM,	  cytoplasmic	  membrane;	  NAG,	  N-­‐acetyl-­‐glucosamine;	  NAM,	  	  698	  
N-­‐acetyl-­‐muramic	  acid;	  UP,	  undecaprenyl-­‐phosphate;	  UPP,	  undecaprenyl-­‐pyrophosphate.	  	  699	  
Amino	  acids	  are	  symbolized	  by	  small	  grey	  circles.	  Lipid	  II	  consists	  of	  the	  NAG/NAM-­‐700	  
pentapeptide	  building	  block,	  covalently	  linked	  to	  the	  lipid	  carrier	  molecule	  UP	  via	  a	  701	  
pyrophosphate	  ester	  bridge.	  The	  steps	  of	  cell	  envelope	  biosynthesis	  linked	  to	  UP	  are	  referred	  702	  
to	  as	  “Lipid	  II	  cycle”.	  CAMPs	  are	  placed	  next	  to	  the	  step	  they	  inhibit.	  703	  
	  704	  
Fig.	  2.	  Models	  of	  the	  effect	  of	  changes	  in	  the	  bacterial	  cell	  surface	  in	  CAMPs	  resistance.	  CM,	  705	  
cytoplasmic	  membrane;	  CW,	  cell	  wall;	  WTA,	  wall	  teichoic	  acids;	  LTA,	  lipoteichoic	  acids.	  CAMPs	  706	  
are	  depicted	  as	  red	  stars.	  707	  
A,	  cell	  envelope	  in	  the	  absence	  of	  D-­‐alanylation	  of	  TAs	  and	  L-­‐lysinilation	  of	  membrane	  708	  
phospholipids.	  Local	  concentration	  of	  CAMPs	  is	  increased	  presumably	  by	  electrostatic	  709	  
interactions	  with	  the	  cell	  envelope.	  CAMPs	  can	  reach	  the	  cell	  membrane	  and	  interact	  with	  710	  
their	  targets.	  711	  
B,	  electrostatic	  hindrance	  model	  for	  CAMP	  resistance.	  D-­‐alanylation	  of	  TAs	  and	  L-­‐lysinylation	  of	  712	  
membrane	  phospholipids	  decrease	  the	  net	  negative	  charge	  of	  the	  cell	  envelope	  and	  the	  local	  713	  
concentration	  of	  CAMPs.	  714	  
C,	  electrostatic	  and	  steric	  hindrance	  model.	  D-­‐alanylation	  of	  TAs	  modifies	  the	  cell	  wall	  715	  
structure	  making	  it	  less	  permeable	  to	  CAMPs.	  	  716	  
Fig.	  3.	  Schematic	  representation	  of	  the	  postulated	  models	  of	  action	  of	  ABC	  transporters	  717	  
conferring	  CAMP	  resistance.	  718	  
A,	  LanFEG	  and	  BcrAB	  transporters.	  Transporters	  are	  shown	  in	  green,	  and	  ATP-­‐hydrolysis	  and	  719	  
substrate	  translocation	  are	  indicated	  by	  black	  solid	  and	  dashed	  arrows,	  respectively.	  CAMPs	  720	  
are	  shown	  as	  red	  stars.	  1)	  Transport	  assisted	  by	  NukH-­‐type	  immunity	  proteins.	  2)	  Binding	  of	  721	  
CAMPs	  by	  NisI-­‐type	  immunity	  proteins.	  3)	  Hydrophobic	  vacuum-­‐cleaner	  model	  of	  efflux	  722	  
mechanism.	  4)	  CAMPs	  (bacitracin)	  bind	  to	  the	  pyrophosphate	  group	  of	  UPP	  preventing	  its	  723	  
dephosphorylation	  by	  undecaprenyl	  pyrophosphate	  phosphatase	  (UppP;	  pink	  pentagon);	  UPP	  724	  
and	  UP	  molecules	  are	  shown	  schematically	  and	  dephosphorylation	  is	  indicated	  by	  a	  black	  725	  
arrow.	  IM,	  immunity	  protein.	  726	  
24	  
	  
B,	  BceAB-­‐type	  transporters.	  5)	  Sensing,	  6)	  resistance	  and	  7)	  dual	  function	  transport	  systems.	  727	  
Signaling	  between	  the	  transporters	  (green)	  and	  the	  TCS	  (blue)	  is	  indicated	  by	  a	  double-­‐headed	  728	  
black	  arrow.	  Phosphotransfer	  within	  TCS	  and	  gene	  activation	  are	  indicated	  by	  black	  arrows,	  729	  
and	  the	  increased	  expression	  of	  transporter	  genes	  is	  indicated	  by	  straight	  dotted	  arrows.	  The	  730	  
positions	  of	  promoters	  relative	  to	  genes	  were	  chosen	  arbitrarily.	  Likely	  dimerization	  of	  BceB-­‐731	  
type	  permease	  subunits	  is	  not	  shown	  for	  reasons	  of	  simplicity.	  HK,	  histidine	  kinase;	  RR,	  732	  





Table	  1:	  Summary	  of	  ABC	  transporters	  main	  characteristics.	  Based	  on	  (Gebhard,	  2012).	  
	   LanFEG	   BcrABa	   BceAB	  
Domain	  architecture	   Permeases	   of	   200–250	   aab	   and	   six	   TMb	  
helices	  each	  
Permeases	  of	  approximately	  230	  aa	  with	   six	  
predicted	  TM	  helices	  
Permease	   of	   approximately	   650	   aa	   and	   10	  
TM	   helices,	   with	   a	   large	   –	   approx.	   200	   aa-­‐	  
extracellular	   domain	   located	   between	  
helices	  VII	  and	  VIII	  
Direction	  of	  substrate	  transport	   Export	   (the	   lantibiotic	   is	   removed	   from	   the	  
cytoplasmic	   membrane	   to	   the	   culture	  
supernatant)c	  	  
Unknown	  (export	  postulated)d	  	   Unknown.	   Import	   suggested,	   followed	   by	  
cytoplasmic	   enzymatic	   inactivation	   of	   the	  
CAMP	  through	  degradatione	  	  
Associated	  proteins	   Immunity	   proteins:	   LanI-­‐type	   proteins	  
(tethered	  to	  the	  membrane	  surface	  via	  an	  N-­‐
terminal	   lipoprotein	   anchor)	   and	   LanH-­‐type	  
proteins	   (contain	   three	   TM	   helices	  with	   the	  
N-­‐terminus	  located	  intracellularly)	  
Undecaprenyl-­‐pyrophosphatase	  (UppP)	   BceRS-­‐like	  TCSb	  
Regulationd	   Mostly	   regulated	  by	   a	   TCS	  with	  prototypical	  
periplasmic	   sensing	   HKb,f	   and	   OmpR	   family	  
RRb.	   Others	   by	   XRE	   family	   transcriptional	  
regulators	  
Mostly	  regulated	  by	  a	  TCS	  with	  IM-­‐HKb,	  f	  and	  
OmpR	   family	   RR.	   Others	   by	   XRE	  
transcriptional	  regulators	  
BceRS-­‐like	  TCS	  with	   IM-­‐HK	  and	  OmpR	  family	  
RR.	   Transporter	   regulating	   its	   own	  
expression	   in	   response	   to	   CAMPs	   (see	   text	  
for	  details)	  
Physiological	  role	   Mostly	   involved	   in	   self-­‐protection	   of	  
lantibiotic	   producing	   strains	   (some	   are	  
genetically	   associated	   with	   lantibiotic	  
biosynthesis	   genes).	   Rarely,	   AMP	   resistance	  
in	  non-­‐producing	  strains.	  
Resistance	   against	   the	   cyclic	  AMP	  bacitracin	  
in	   producing	   (self-­‐protection)	   and	   non-­‐
producing	  strains	  
AMP	  resistance	  in	  non-­‐producing	  strains	  
Substrates	  	   Lantibiotics	  (nis,	  gall,	  epi,	  nuk,	  sub,	  etc.)g	  and	  
dipeptide	  lantibiotics	  (lact)g	  
Cyclic	  AMP:	  bacg	   Lantibiotics	  (nis,	  sub,	  gall,	  mer)g,	  cyclic	  AMPs	  
(bac),	   lipodepsipeptides	   (end)g,	  
glycopeptides	   (van,	   tei)g,	   peptides	   from	   the	  
immune	   system	   of	   higher	   organisms	   like	  
26	  
	  
cathelicidines	  (LL-­‐37,	  ind,	  ovi)g,	  and	  defensins	  
(hBD3,	  bre,	  ple)g	  
a	  For	  simplicity	  only	  the	  BcrAB	  transporters	  are	  included.	  The	  reader	  is	  referred	  to	  Gebhard	  2012	  (Gebhard,	  2012)	  for	  additional	  information	  on	  
YydIJ.	  
b	   aa:	   amino	   acids;	   TM:	   transmembrane;	   TCS:	   two	   component	   systems;	  HK:	   Histidine	   kinase;	   RR:	   Response	   regulator;	   IM-­‐HK:	   intramembrane-­‐	  
sensing	  histidine	  kinase.	  
c	  (Otto	  et	  al.,	  1998;	  Stein	  et	  al.,	  2003;	  Okuda	  et	  al.,	  2008)	  
d	  (Gebhard,	  2012)	  
e	  (Rietkötter	  et	  al.,	  2008;	  Hiron	  et	  al.,	  2011)	  
f	  (Mascher	  et	  al.,	  2006).	  
g	   act:	   actagardine;	   bac:	   bacitracin;	   bre:	   brevinin;	   end:	   enduracidin;	   epi:	   epidermin;	   gall:	   gallidermin;	   ind:	   indolicidin;	   lact:	   lacticin	   3147;	  mer:	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